NCT01267812View on ClinicalTrials.gov

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 3, 2011

Primary Completion Date

November 2, 2020

Study Completion Date

November 2, 2020

Conditions
Contiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaRecurrent Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
Interventions
DRUG

bortezomib

Given SC or IV

BIOLOGICAL

rituximab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

RNA analysis

Correlative studies

GENETIC

gene expression analysis

Correlative studies

GENETIC

DNA analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

pharmacogenomic studies

Correlative studies

OTHER

Questionnaire Administration

Trial Locations (2)

91010

City of Hope Medical Center, Duarte

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01267812 - Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | Biotech Hunter | Biotech Hunter